1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hemophilia A-Pipeline Insights, 2016

Hemophilia A-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Hemophilia A-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Hemophilia A. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Hemophilia A. DelveInsight’s Report also assesses the Hemophilia A therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Hemophilia A
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Hemophilia A pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Hemophilia A and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Hemophilia A-Pipeline Insights, 2016

Illustrative Table of contents

- Hemophilia A Overview
- Hemophilia A Pipeline Therapeutics
- Hemophilia A Therapeutics under Development by Companies
- Hemophilia A Filed and Phase III Products
- Comparative Analysis
- Hemophilia A Phase II Products
- Comparative Analysis
- Hemophilia A Phase I and IND Filed Products
- Comparative Analysis
- Hemophilia A Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Hemophilia A - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hemophilia A - Discontinued Products
- Hemophilia A - Dormant Products
- Companies Involved in Therapeutics Development for Hemophilia A
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Hemophilia A, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Hemophilia A Assessment by Monotherapy Products
- Hemophilia A Assessment by Combination Products
- Hemophilia A Assessment by Route of Administration
- Hemophilia A Assessment by Stage and Route of Administration
- Hemophilia A Assessment by Molecule Type
- Hemophilia A Assessment by Stage and Molecule Type
- Hemophilia A Therapeutics - Discontinued Products
- Hemophilia A Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Hemophilia A, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Hemophilia A Assessment by Monotherapy Products
- Hemophilia A Assessment by Combination Products
- Hemophilia A Assessment by Route of Administration
- Hemophilia A Assessment by Stage and Route of Administration
- Hemophilia A Assessment by Molecule Type
- Hemophilia A Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021. The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.